 "135 cr Covid vaccine doses to be available between Aug to Dec: Govt to SC")
The Centre has informed the Supreme Court that a total of 135 crore COVID-19 vaccines will be available in India between August to December.
The Centre informed about the projected availability of COVID-19 vaccines in an affidavit filed in the suo motu case on COVID-19 management initiated by the apex court.
As per the affidavit, out of the 135 crore vaccines, the estimated availability of Covishield doses is 50 crores, while of Covaxin doses is 40 crores.
It said that Russian made Sputnik V vaccine's estimated availability is 10 crores doses.
The affidavit filed by the Central government also informed that the Bio E Sub unit vaccine's 30 crore doses will be available while Zydus Cadila DNA vaccine's 5 crore doses will be available.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app